Otolaryngology

Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The Series B round begins as Ikena prepares to add a TEAD inhibitor to its roster of clinical programs and pushes a first-in-class KRAS asset through lead optimization. Celgene collaborated with Ikena on its kynureninase and AHR antagonist programs, fuelling the startup's claims, its assets are differentiated from failed IDO1 inhibitors, and other candidates started moving through preclinical. The progress has set Ikena to raise USD 120 million. Omega Funds led the series B round with assists ...